SCHEMBL20412474

SCHEMBL20412474

CCCCCCNC(=O)c1cccc(-c2c3ccc(=O)cc-3oc3cc(O)ccc23)c1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 3/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ MEN1 O00255 2/20 0.49
▸ POLB P06746 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ ATM Q13315 1/20 0.49
▸ PLEC Q15149 1/20 0.49
▸ FOLH1 Q04609 1/20 0.47
▸ ALPL P05186 1/20 0.47
▸ ALPI P09923 1/20 0.47
▸ ALPG P10696 1/20 0.47
▸ TLR7 Q9NYK1 1/20 0.47
▸ CA9 Q16790 4/20 0.46
▸ CA1 P00915 3/20 0.46
▸ CA2 P00918 3/20 0.46
▸ CA12 O43570 2/20 0.46
▸ ALB P02768 2/20 0.46
▸ ESR1 P03372 1/20 0.46
▸ DNASE1L3 Q13609 1/20 0.45
▸ PRMT1 Q99873 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24943213 0.90 USP2 (0.51) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL18211595 0.84 ALB (0.59) USP2L3MBTL1FOLH1ALBESR1
SCHEMBL18162919 0.84 ALB (0.59) USP2L3MBTL1FOLH1ALBESR1
SCHEMBL13287065 0.84 USP2 (0.60) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL13286956 0.83 ALB (0.60) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL24943567 0.80 USP2 (0.52) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL13815114 0.79 CA1 (0.71) CA9CA1CA2CA12
SCHEMBL20600872 0.78 USP2 (0.55) USP2L3MBTL1MEN1POLBKMT2A
Acexamic Acid SCHEMBL30634509 0.78 USP2 (0.55) USP2L3MBTL1MEN1POLBKMT2A
SCHEMBL13219607 0.78 CA1 (0.72) CA9CA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180209986-A1 COMPOSITIONS AND METHODS FOR DETECTING CANCER CELLS IN A TISSUE SAMPLE ISI LIFE SCIENCES, INC. (US) 2018-07-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180209986-A1 COMPOSITIONS AND METHODS FOR DETECTING CANCER CELLS IN A TISSUE SAMPLE FOLR1, FOLR2, FOLH1 USP2 4100/4885L3MBTL1 3662/4885MEN1 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback